key: cord-1056291-m3dofc93
authors: Shirazi, Sajjad; Stanford, Clark M.; Cooper, Lyndon F.
title: Testing for COVID-19 in dental offices: mechanism of action, application and interpretation of laboratory and point-of-care screening tests
date: 2021-05-04
journal: J Am Dent Assoc
DOI: 10.1016/j.adaj.2021.04.019
sha: a8542fc9b816e31283aa30eb2917a9f8881b4e3d
doc_id: 1056291
cord_uid: m3dofc93

Background The dental office potentially possesses all transmission risk factors for SARS-CoV-2 virus. Anticipating the future widespread use of COVID-19 testing in the dental offices, this article is a proactive effort to provide dental health care providers with current and necessary information surrounding the topic. Methods All relevant and recent guidelines from CDC and FDA, as well as online resources and review articles were consulted. Results Routine COVID-19 screening and triage protocols are unable to detect all infected individuals. With the advancements in diagnostic tools/techniques, COVID-19 testing at home or in the dental office may provide dentists with abilities to evaluate the disease status of their patients. At home or point-of-care tests, providing results within minutes of being administered, would allow for appropriate measures and rapid decisions about dental patients' care process. In this review, we familiarize the reader with current available laboratory and point-of-care COVID-19 screening methods, and, identify and elaborate the options available for use by dentists as well as the regulatory requirements of test administration. Conclusion Dentists need to be familiar with COVID-19 point-of-care testing options. While contributing to public health, such tests may deliver rapid, accurate and actionable results to clinical and infection control teams to enhance the safe patient flow in dental practices.

The dental setting is a unique environment in the current pandemic since it potentially possesses all transmission risk factors for SARS-CoV-2 virus, as stated by the Centers for Diseases Control and Prevention (CDC) 1 . The infection occurs when the virus is inhaled or deposited on mucous membranes including the nose and mouth 2 . Currently, there is no direct data available to assess the risk of SARS-CoV-2 transmission in dental practice (i.e. patient to patient, provider to patient, patient to provider, different procedures, etc.). Irrespective of the path of transmission, an estimated 0.9% of US dentists 3 and an estimated 3.1% of dental hygienists in the U.S. 4 were SARS-CoV-2 positive.

In view of the recent advancements in diagnostic and screening tools/techniques for COVID-19, dental practices may directly benefit from the ability to evaluate the disease status of patients while contributing to broader public health efforts. Rapid Point-of-Care (POC) tests provide results within minutes, allowing for appropriate measures and rapid decisions about next steps in the care process. SARS-CoV-2 induced COVID-19 represents only the latest manifestation of a 150 year history of epidemic disease patterns and transmission of contagious diseases. As such, the rapid screening and diagnostics testing approaches created/adapted for COVID-19 will be applicable for future viral pathogens, and thus, the dental office should be prepared to adopt standardized workflows as common future practice.

Anticipating the current and future need for pathogen testing in the dental offices, this report will familiarize the reader with the latest available laboratory methods for COVID -19 screening and diagnosis, and then, will identify and further elaborate the options available for use by dentists as well as the regulatory requirements of administration of those tests. Fundamentals of testing for COVID-19 detection is summarized in Figure 1 , A-C. Essential terminology to better understand and utilize COVID-19 resources is described in Text box 1.

The authors reviewed COVID-19 CDC guidelines for the up-to-date (as of 04/05/2021) information regarding testing options and related matters 5, 6 . The FDA website was consulted for the latest authorized in vitro diagnostic tests 7-9 . Pubmed/MEDLINE was searched for review articles regarding mechanism of action of different testing options.

Screening testing: is performed to identify infected individuals before development of symptoms or those infected individuals without signs or symptoms (asymptomatic), or suspected exposure to COVID-19, who may be contagious in order to prevent the spread of virus. Examples of screening include testing plans developed by a workplace to test all employees returning to the workplace regardless of exposure or signs and symptoms. These tests are designed to have a higher false positive rate (lower sensitivity) but high specify (false negatives) with the desire to screen for and capture those with the disease at the risk of involving the uninfected with more invasive testing.

Diagnostic testing: these tests also look for occurrence at the individual level but are performed when there is a particular reason to suspect that an individual may be infected. They are performed when a person has signs or symptoms consistent with COVID-19, when a person is asymptomatic but has recent known or suspected exposure to COVID-19, or when testing to determine resolution of infection. These are designed with high sensitivity (lower false positives) and high specificity (low false negatives) in populations considered at high risk for disease (often measured by positive predictive values). As implied, if the test is applied to a high-risk population, then a positive test will have a greater positive predictive value than the same result in a population where there is a low disease prevalence (and thus a much higher rate of false positive values).

Surveillance testing: this test is used to monitor population-or community-level outbreak of COVID-19, or to characterize the incidence and prevalence of COVID-19. These are performed on de-identified specimens (typically, pooled), and the results are not linked to individuals. Thus, surveillance testing is used for health policy and not patient care. It may be random sampling of a certain percentage of a specific population to monitor for increasing or decreasing prevalence and determining the population effect from community interventions such as social distancing. See Table 1 for summarized comparison of different testing strategies.

Pretest probability: A Bayesian statistical approach uses the likelihood the person being tested really has the infection before the test, a test is performed, and the pre-and post-test probabilities are compared creating a likelihood index. Thus, a diagnostic test performs optimally for detecting an "infection" when the pretest probability is high (meaning in the test population there is already a high rate of disease). The pretest probability increases with increasing prevalence in the population, and clinical indications or symptoms of illness in the person being J o u r n a l P r e -p r o o f Diagnostic sensitivity and specificity: Sensitivity is the ability of a test to correctly identify persons with infection and is the proportion of true positive results to the sum of true positive and true negative results. Specificity is the ability to correctly rule-out infection and is the proportion of true negative results to the sum of true negative and false positive ones. False negative results are the most consequential and thus screening tests are based to capture those at risk.

where there is no clinical reference standard test with 100% sensitivity and specificity, the sensitivity and specificity of a new test will be evaluated against an imperfect reference standard and will be respectively reported as positive percent agreement (the proportion of individuals with the target condition by the imperfect reference standard who test positive) and negative percent agreement (the proportion of individuals free of the target condition by imperfect reference standard who test negative). The challenge is that the benchmark for the positive percent agreement will change over time, so this is at best a field measure supporting just-in-time clinical decision making.

Analytical sensitivity: also referred to as limit of detection, is the minimum amount of SARS-CoV-2 viral particle count detected and/or quantitatively determined ≥ 95% of the time by means of the utilized test.

Analytical specificity: is the ability of a specific test platform to detect its intended target i.e., SARS-CoV-2 virus. Cross-reactivity and target interference impacts analytical specificities.

Cross-reactivity occurs when patient's sample contains SARS-CoV-2 as well as other genetically related organisms, and the assay's analytic reagents (e.g., PCR primers or Antibodies) cross-react or anneal to sequences or antigens of these organisms, generating a false positive result(s).

Interference occurs when the specimen is contaminated with endogenous elements like hemoglobin or medications; or exogenous inhibitory substances such as lipstick, hand cream, powdered gloves and serum separators. These inhibit chemical/ biochemical reactions essential to the test and increase false negative result(s).

Positive predictive value: is the probability a patient with a positive test result most likely has the infection (or the test target). It is affected by general prevalence, test sensitivity and pretest probability in the population of interest. In a high-prevalence setting, the positive predictive value increases, meaning it is more likely persons testing positive are truly positive for disease (or appropriately reactive in the case of an antibody test platform). In turn, as prevalence in the population declines, false positive rates will increase as they are inversely related. Test J o u r n a l P r e -p r o o f

Laboratory testing for SARS-CoV-2 involves detection of the viral RNA using nucleic acid amplification tests (NAATs), the viral structural (or nucleocapsid) proteins using antigen tests, or the virus-specific human adaptive immune response (antibodies) using immunoassays ( Figure 1-C, Figures 2-4 ). An optimum test for direct diagnosis of SARS-CoV-2 infection must have low infrastructural requirements, short turnaround time, minimum batching, high throughput, high accuracy, and low cost to allow public access 10 . Table 3 summarizes the important aspects of each testing method.

The current recommended test platform for diagnosis of SARS-CoV-2 infection involves detection of viral RNA using NAATs. The FDA authorized methods in this category utilize a variety of platforms. A detailed description of NAAT-based techniques has been widely discussed in the literature [11] [12] [13] [14] [15] [16] [17] [18] . Figure 2 demonstrates a simplified and general process of NAATs.

A single negative NAAT result does not exclude infection, and factors such as exposure risk and potential laboratory errors must be considered. False negative result(s) may occur if the specimen was obtained: too early after exposure or was not collected, transported, or handled/treated properly; if the nucleic acid extraction step was improper; or if the sample and the specificity of the test increases, the false-positive rate decreases and the positive predictive value increases. When a test is used in a population where prevalence is low, the positive predictive value drops because there are more false-positive results, since the pre-test probability is low.

Negative predictive value: is the possibility that a patient with a negative test result most likely does not have the infection. It is affected by pretest probability and prevalence. In a highprevalence setting, the negative predictive value declines whereas in a low-prevalence setting, it increases. Pretest probability and test sensitivity have the highest impact on false-negative rates.

As the pretest probability decreases, the false-negative rate decreases and the negative predictive value increases. As the sensitivity of the test increases, the false-negative rate decreases and the negative predictive value increases. 

Antigen tests directly detect viral structural proteins without any amplification steps and do not require trained personnel and special laboratory instruments or reagents. The tests utilize antibodies reactive to SARS Co-V-2 proteins to detect infection. While they are rapid, simple, and relatively inexpensive immunoassays they only reveal the active/current COVID-19 infection and contagiousness. A description of methods for antigen detection has been clearly described in the literature [14] [15] [16] [17] [18] .

The currently authorized antigen tests are only performed on nasopharyngeal or nasal swab specimens. They are not restricted to specific age groups and many can be used at POC with results in about 15 minutes. They can be used in screening/diagnostic testing situations in which the person is suspected for COVID-19 or has a known exposure to a person with COVID-J o u r n a l P r e -p r o o f 19. They can also be utilized as screening tests on asymptomatic persons to detect or exclude COVID-19, or to determine whether a person who previously was diagnosed with COVID-19 remains infectious. Screening testing with antigen tests is also beneficial when repeat testing could quickly identify persons with a SARS-CoV-2 infection, thus alerting health care workers to institute prevention and control measures. There is value in providing immediate results with antigen tests where a rapid test turnaround time is required, even though they may have lower sensitivity than NAATs 23 . Figure 3 describes a simplified process of antigen tests.

Inherently, antigen screening platforms are less sensitive than genetic PCR-based detection platforms (e.g., NAATs) but have a similarly high specificity. They are less reliable in the clinical diagnosis of COVID-19 patients with low viral load. Antigen test's best clinical performance is during early symptomatic infection, when the viral load is considered to be the highest (Figure 1-B) 14, 18 .

One limitation with antigen testing is the potential for higher false negative results. False negative results occur because of inherent low sensitivity or if the antigen level in specimens collected is below the detection limit of the assay or the time of collection before or much later following symptom onset. Also, the stability of antigens in biologic samples can degrade as a function of time and temperature following sample collection. Since positive and negative predictive values are highly dependent on communal COVID-19 prevalence, false negative test results are statistically more likely during peak activity when prevalence of disease is high.

Negative antigen test results should be handled differently depending on the test, its stated performance characteristics, and intended application (e.g., clinical diagnosis, screening). In general, negative antigen test results should be considered presumptive, meaning that they are 

Serologic tests utilize antibody-antigen recognition by using cloned or recombinant SARS-CoV-2 antigens to detect patient antibodies generated against the virus. Current serologic tests authorized for emergency use by FDA, detect IgM, IgG or total antibody. A detailed description of these techniques is reported elsewhere 10, 12, 24, 25 . Figure 4 depicts a simplified process of antibody detection tests.

Current FDA authorized serologic tests are performed using whole venous or fingerstick blood, serum, or plasma with comparable sensitivity and specificity between whole blood and serum. They are not very costly or restricted to any certain age, are relatively easy to use and generally return results in about 15 to 90 minutes depending on the assay, some of which may require trained laboratorians and specialized instruments. Almost all the current tests are qualitative (providing a result that is positive, negative, or indeterminate) rather than quantitative (providing a quantitative assessment of antibody levels). Some serologic tests are available for POC use and utilize lateral flow immunoassay (LFIA) with fingerstick blood collection. Note, serologic testing, by itself, should not be used to establish the presence or absence of SARS-CoV-2 infection or reinfection.

Serologic tests are both less sensitive and specific than NAATs and most of antigen tests, because they must contend with the inherent variability of the human polyclonal antibody response. In addition, they inherently measure a response to an infection, not the infection itself.

The delay required for B /Plasma Cells to generate a humoral antibody response and for the body to mount a full polyclonal humoral immunity does not allow for the use of serology tests early in the course of infection 14, 19 . Serological tests can be used to determine different aspects of immune response and functionality of antibodies. They are also indicated in epidemiologic and surveillance studies to mass-screen the prevalence of COVID-19 and identify asymptomatic patients or carriers and also to detect the presence, nature and the extent of the humoral immune response against SARS-CoV-2 infection which also allows to differentiate between past and current infection as well as its progress. Serology tests are also useful in vaccine studies and investigation of late complications while NAATs tests may yield false negative results due to low viral loads in the tested samples. They can also be offered in adjunction to NAATs or antigen tests for persons who present 9-14 days after illness onset, during which, the sensitivity of NAATs is decreasing, and the sensitivity of serologic testing is increasing 14, 15, 19, 20, 25 . Table 4 summarizes the relationship between the results of antibody tests, NAATs and clinical manifestation of COVID-19. The immunological response to SARS-CoV-2 infection is not limited to antibody production; the cellular responses of T-cells and macrophages against the invading virus may play a significant, yet, currently under examined role in disease progression.

Potential cellular assessments may prove of additional value 26 .

To date, data is limited regarding the nature, kinetics and dynamics of immunological response(s) to SARS-CoV-2 infection 27 and it can vary with age, gender, and presence of comorbidities as well as characteristics of the viral load and variant infectivity/transmissibility. It is suggested, seroconversion after exposure to SARS-CoV-2 is similar to other acute viral infections, with IgG concentration beginning to rise as IgM concentration reaches a plateau and then declines. IgM usually becomes undetectable weeks to months following infection, while IgG may remain detectable for months or years (Figure 1-B) . Therefore, IgM and IgG are indicative of early/recent and late/past stage responses to the infection. Nevertheless, the role of virus-specific IgA against SARS-CoV-2 infection in humans should be emphasized 14, 15, 28 .

Recent data suggest that IgA-mediated mucosal immunity is a critical defense mechanism against SARS-CoV-2 at the individual level, which may reduce infectivity of human secretions, J o u r n a l P r e -p r o o f and viral transmission. Secretory IgA can be easily measured in saliva. This may also encourage the development of vaccines that induce specific mucosal IgA responses against SARS-CoV-2 29 . In addition, it provides the chance to test for antibodies in a samples including saliva, respiratory tract secretions and other body fluids in addition to blood products 15 

The American Dental Association (ADA) considers point of care testing/screening of patients for medical conditions, including COVID-19, within a dentist's scope of practice if such conditions could complicate dental care or put the patient and dental staff at risk. In this line, FDA includes dentists among those professionals who can test for COVID-19, and CDC recommends dental facilities to consider implementing pre-procedure testing for COVID-19 6,31 .

The ADA has released a toolkit called "COVID-19 & Lab Testing Requirements Toolkit" to help guide dentists interested in offering their patients rapid response, point-of-care COVID-19 screening/testing within their practices. It provides information for dentists on applying for the federal certification required to offer this type of testing. The toolkit also includes compliance requirements, tips for developing a waived testing program in dental practices, COVID-19 test reporting requirements, and guidance on medical benefit plan claim filing for inoffice COVID-19 testing. Any dental practice that plans to incorporate testing for COVID-19 into their screening protocol is considered a clinical laboratory and must comply with regulations set by the Clinical Laboratory Improvement Amendments (CLIA) law, which establishes quality J o u r n a l P r e -p r o o f standards for all laboratory testing to ensure accuracy, reliability and timeliness of patient test results regardless of where the test was performed 7,32,33 . Specific requirements for each state, and guidance on patient medical benefit plan claim filing for in-office COVID-19 testing is provided in ADA's toolkit 32 .

Dentists who register for a CLIA certificate of waiver for their practices must only perform tests that have been classified as "waived" tests which include some NAATs, antigen and antibody tests, and must follow the manufacturer's instructions for each test 32, 33 . CDC has provided comprehensive guidelines and useful educational materials for point of care testing and infection control 6,33,34 . According to CDC reporting guideline, dental offices with CLIA certificates are considered testing sites and must report both the positive and negative results of COVID-19 diagnostic and screening tests that they perform using in-home diagnostic or screening tests to the appropriate state or local public health department 32, 35 . CDC guidelines must be followed for specimen collection and handling of POC tests 33, 36 The POC testing options and technologies for COVID-19 testing are growing and evolving fast. To date, multiple POC testing options are authorized, and dental offices with CLIA certificate would be eligible to utilize and benefit from them 7 . Yet, there exist no salivabased POC antigen or antibody tests approved for use. Appendix Tables 1-3 summarize the characteristics of all currently authorized POC tests for COVID-19. Large scale assessment of these tests' sensitivity and specificity are not widely reported.

FDA has issued EUA for an Over the Counter (OTC) and a prescription-only NAAT based diagnostic tests, that can be fully self-administered and provide rapid results at home, using nasal swab samples in individuals two years of age or older. They are also authorized for POC use but samples must be collected by a healthcare provider. Many other NAAT-based assays are also authorized for at-home specimen collection with subsequent remote laboratory processing 7 . Interestingly, there are some POC multiplexed RT-PCR based assays for simultaneous rapid and qualitative detection and differentiation of SARS-CoV-2, influenza A and/or influenza B viruses in less than an hour. There is also an automated POC assay that utilizes isothermal nucleic acid amplification technology for qualitative detection of SARS-CoV-2 in direct (no need for transport medium) nasal, nasopharyngeal and throat swabs in less than 13 minutes (Appendix table 1).

Furthermore, the FDA has issued EUA for an OTC fully at-home diagnostic test for COVID-19 which is a lateral flow antigen test that uses a nasal swab sample from any individual 2 years of age or older and gives the result within 20 minutes. Other fully at-home antigen based tests are also available with prescription. There are also antigen tests for simultaneous detection and differentiation of SARS-CoV-2, influenza A and/or influenza B viruses which gives results within 15 minutes. This is in addition to multiple POC antigen tests that have been authorized for POC use 8 (Appendix table 2) .

Currently, a number of serology tests are authorized for POC use and detect IgG and/or IgM from fingerstick blood in about 10-20 minutes 9 (Appendix table 3 ).

These options, and particularly such tests that can be fully administered entirely outside of a lab or healthcare setting, may deliver rapid, accurate, and actionable results to dental clinical and infection control teams with the promise of contributing to enhanced infection control in dental and other health care settings. In addition, the ability for detection and differentiation of influenza (flu) and COVID-19 which may present with similar symptoms will give additional guidance for effective triage and patient management.

CDC has reported many people residing in the United States have seen a dentist over the past year, but no other medical professional 37 . Therefore, dental offices/settings could have a 

These findings highlight that basic patient triage protocols alone would not identify all individuals who are infected. Therefore, timely, accurate (highly sensitive and specific) and rapid screening and testing that can distinguish COVID-19 cases from healthy or other virus-infected individuals is an essential need to take required actions, optimized patient care, maintain dental patients' and treatment providers' safety, and to contain and prevent disease spread. POC tests, that can be fully administered entirely outside of a lab or healthcare setting, will deliver rapid, accurate, and actionable results to dental clinical and infection control teams and will contribute greatly to safe patient flow in dental practices. In addition, the ability for detection and differentiation of influenza (flu) and COVID-19 which present with similar symptoms will give insights for effective triage and patient management.

Dental care must continue to offer safety, despite this or future pandemic(s). Mitigation of SARS-CoV-2 transmission requires the application of engineering and administrative controls, and the use of personal protective equipment. While the promise of vaccines may reduce levels of the virus within communities, risks will remain until this virus falls into the annual viral background and surveillance strategies at the community level remain important.

Testing for SARS-CoV-2 at the point of care offers another control mechanism contributing to and enhancing the real and perceived safety of care in the dental office setting. Several options for POC testing within the dental office are emerging (with additional responsibilities) and can provide additional guidance to reduce disease transmission in the dental office. 

COVID-19) -Transmission

Characteristics and Detection Rate of SARS-CoV-2 in Alternative Sites and Specimens Pertaining to Dental Practice: An Evidence Summary

Estimating COVID-19 prevalence and infection control practices among US dentists

COVID-19 Prevalence and Related Practices among Dental Hygienists in the United States

Individual EUAs for Molecular Diagnostic Tests for SARS-CoV-2. FDA. Published

Individual EUAs for Antigen Diagnostic Tests for SARS-CoV-2. FDA. Published

FDA. Individual EUAs for Serology Tests for SARS-CoV-2. FDA. Published

Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review

Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance

COVID-19: molecular and serological detection methods

Current diagnostic tools for coronaviruses-From laboratory diagnosis to POC diagnosis for COVID-19

SARS-CoV-2 pandemic: a review of limitations

Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics

Evaluation of current diagnostic methods for COVID-19

Detection of COVID-19: A review of the current literature and future perspectives

Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art

Molecular Diagnosis of Coronavirus Disease

Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings

COVID-19 diagnosis -A review of current methods

The trinity of COVID-19: immunity, inflammation and intervention

The first 12 months of COVID-19: a timeline of immunological insights

Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays

IgA dominates the early neutralizing antibody response to SARS-CoV-2

ADA Supports Point of Care COVID-19 Testing by Dentists

Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19

SARS-CoV-2 Infection in Asymptomatic Pediatric Dental Patients

SARS-CoV-2 positivity in asymptomaticscreened dental patients. medRxiv

What is the rate of COVID-19 infection in a population seeking dental care?